FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
In consideration for the current capsid license, Voyager will receive $15M upfront and is eligible to receive up to $305 million in associated potential development, regulatory, and commercial milestone payments, as well as tiered mid- to high-single digit …